Literature DB >> 2791189

Factors causing dose variability in drug administration.

R Demicheli1, A Jirillo, G Bonciarelli, F Lonardi, M Pradella, M Balli.   

Abstract

The variability of the drug dose actually given to cancer patients was analyzed. Three variability factors were quantitatively examined (body surface calculation, personalized dose calculation, and drug residuum in commercially available vials) and their variability was experimentally measured. A systematic reduction (mean, 7%; range, 2%-15%) and a random variability (4%-5%) of the dose given were demonstrated. These results draw attention to the role of some of the procedures of routine clinical activity in determining the amount of drug actually delivered. The analysis suggests that personalization of doses must be very accurate in both measurement and calculation and that the staff giving the drug needs to be carefully informed about the importance of drug residuum. The variability of the delivered dose can lead to the misclassification of patients in investigations on the dose-response relationship. This factor may be added to pitfalls previously reported to affect this type of retrospective analysis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2791189     DOI: 10.1007/bf00257443

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  10 in total

1.  CLINICAL STUDIES OF DICHLOROMETHOTREXATE (NSC 29630).

Authors:  E FREI; C L SPURR; C O BRINDLEY; O SELAWRY; J F HOLLAND; D P RALL; L R WASSERMAN; B HOOGSTRATEN; B I SHNIDER; O R MCINTYRE; L B MATTHEWS; S P MILLER
Journal:  Clin Pharmacol Ther       Date:  1965 Mar-Apr       Impact factor: 6.875

2.  VINCRISTINE (NSC-67574): DOSAGE AND RESPONSE IN ADVANCED BREAST CANCER.

Authors:  R GRINBERG; T NEMOTO; T L DAO
Journal:  Cancer Chemother Rep       Date:  1965-04

3.  Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin.

Authors:  G N Pillai; F B Hagemeister; W S Velasquez; J A Sullivan; D A Johnston; J J Butler; C C Shullenberger
Journal:  Cancer       Date:  1985-02-15       Impact factor: 6.860

4.  Plasma and urinary levels of adriamycin in man.

Authors:  R Rosso; C Ravazzoni; M Esposito; R Sala; L Santi
Journal:  Eur J Cancer       Date:  1972-08       Impact factor: 9.162

5.  The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival.

Authors:  C Redmond; B Fisher; H S Wieand
Journal:  Cancer Treat Rep       Date:  1983-06

6.  Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

Authors:  F M Schabel; D P Griswold; T H Corbett; W R Laster
Journal:  Cancer       Date:  1984-09-15       Impact factor: 6.860

7.  A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy.

Authors:  P Carde; F R MacKintosh; S A Rosenberg
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

8.  High-performance liquid chromatographic analysis of cyclophosphamide.

Authors:  T T Kensler; R J Behme; D Brooke
Journal:  J Pharm Sci       Date:  1979-02       Impact factor: 3.534

9.  Dose-response effect of adjuvant chemotherapy in breast cancer.

Authors:  G Bonadonna; P Valagussa
Journal:  N Engl J Med       Date:  1981-01-01       Impact factor: 91.245

10.  Dose response evaluation of adriamycin in human neoplasia.

Authors:  R M O'Bryan; L H Baker; J E Gottlieb; S E Rivkin; S P Balcerzak; G N Grumet; S E Salmon; T E Moon; B Hoogstraten
Journal:  Cancer       Date:  1977-05       Impact factor: 6.860

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.